Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.
Joseph B. Babigumira
Consultant or Advisory Role - Genentech
Eduardo Santos
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Vincent Percival Antao
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Bruce Wang
Consultant or Advisory Role - Genentech
Chia C. Portera
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Tripthi Kamath
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Louis P Garrison
Consultant or Advisory Role - Genentech